Fallah Ferigol, Hamidikenari Abolhasan, Sajadi Seyed Navid, Sajadi Seyed Rohollah, Shiran Mohammadreza
Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Caspian J Intern Med. 2016 Spring;7(2):133-5.
Clopidogrel is a prodrug that converts in the liver to an active thiol metabolite, which irreversibly inhibits the platelet P2Y12 adenosine diphosphate receptor. It seems that methadone as CYP2C19 inhibitor affects ticlopidine activity in vivo. This study aimed to test the ability of methadone in changing ticlopidine pharmacokinetics.
We conducted a case-control study in 10 subjects. The cases (5 subjects) in our study were addicts who were receiving methadone maintenance treatment (MMT) for preventing opium withdrawal symptoms. The control group were opiate users before starting MMT. In both groups, the patients received clopidogrel (75mg/day) for 5 days. On the 6(th) day, the subjects returned to the clinic, blood samples were taken up to 12 hours following clopidogrel dosing in case and control groups. Plasma concentration of clopidogrel was measured by GC-MAS. Noncompartmental pharmacokinetic analysis was performed using Microsoft Excel software to estimate PK parameters.
In this study, methadone decreased clopidogrel clearance by 25% and increased the AUC0-inf nearly 1.3 fold during the coadministration of clopidogrel as an antiplatelet drug.
A significant decrease in the clearance of clopidogrel during the coadministration of methadone consistent with a decrease in clopidogrel conversion to its active metabolite and this may decrease its efficacy and may have life-threatening consequences for the patients undergoing clopidogerel maintenance therapy.
氯吡格雷是一种前体药物,在肝脏中转化为活性硫醇代谢物,该代谢物不可逆地抑制血小板P2Y12二磷酸腺苷受体。美沙酮作为细胞色素P450 2C19抑制剂似乎会影响噻氯匹定在体内的活性。本研究旨在测试美沙酮改变噻氯匹定药代动力学的能力。
我们对10名受试者进行了一项病例对照研究。我们研究中的病例组(5名受试者)是接受美沙酮维持治疗(MMT)以预防鸦片戒断症状的成瘾者。对照组是开始MMT之前的阿片类药物使用者。两组患者均接受氯吡格雷(75mg/天)治疗5天。在第6天,受试者返回诊所,在病例组和对照组中,在服用氯吡格雷后长达12小时采集血样。通过气相色谱-质谱联用仪测量氯吡格雷的血浆浓度。使用Microsoft Excel软件进行非房室药代动力学分析以估计药代动力学参数。
在本研究中,作为抗血小板药物联合使用氯吡格雷时,美沙酮使氯吡格雷的清除率降低了25%,并使AUC0-inf增加了近1.3倍。
美沙酮联合使用期间氯吡格雷清除率显著降低,这与氯吡格雷向其活性代谢物的转化减少一致,这可能会降低其疗效,并可能对接受氯吡格雷维持治疗的患者产生危及生命的后果。